Non-specialty pipeline forecast as of June 2009

[chantell.reagan]

The following list represents non-specialty pipeline updates for June 2009 from DrugPipelineForecast. Please click on the product name to view update for individual products. To access DrugPipelineForecast, you must be a registered user of DrugManagementForum (click here to register)

Acurox - PDUFA date delayed

alogliptin - complete response letter received; EU filing delayed

alogliptin/pioglitazone - EU filing delayed

arzoxifene - positive Phase III data

Besivance (besifloxacin) - FDA approved (removed from DrugPipelineForecast)

Cambia (diclofenac potassium) oral powder - FDA approved (removed from DrugPipelineForecast)

ceftaroline - positive Phase III data (new entry in DrugPipelineForecast

Certriad - NDA filed

Contrave - positive Phase III data

darusentan - positive Phase III data

Flutiform - more data likely needed

gabapentin (DM-1796) - in Phase III (new entry in DrugPipelineForecast)

gabapentin (DM-5689) - in Phase III (new entry in DrugPipelineForecast)

Gattex - positive Phase III data

Gencaro - FDA denies drug

Intermezzo - PDUFA date delayed

Livalo - awaiting FDA review (new entry in DrugPipeline Forecast)

lomitapide - positive Phase III data (new entry in DrugPipelineForecast)

Loramyc - NDA filed (new entry in DrugPipelineForecast)

lorcaserin - positive Phase III data

LuAA21004 - in Phase III (new entry in DrugPipelineForecast)

Neupro - positive opinion from EU

ondansetron - NDA accepted (new entry in DrugPipelineForecast)

Qnexa - positive Phase III data

Qutenza - orphan drug designation

Restanza - FDA advisory board recommends against drug

Silenor - NDA resubmitted

Syncria - positive Phase III data

telmisartan/amlodipine - positive Phase III data (new entry in DrugPipelineForecast)

Victoza - positive Phase III data

vilazodone - positive Phase III data (new entry in DrugPipelineForecast)

Zipsor (diclofenac potassium) liquid-capsules - FDA approved (removed from DrugPipelineForecast)

Zypadhera - positive Phase III data

For more information, or to search additional drugs, please see DrugPipelineForecast